Seattle Genetics, Inc. and partner Takeda Pharmaceuticals recently reported results from a post-hoc analysis evaluating progression-free survival in patients treated with Adcetris.
http://www.investopedia.com/stock-analysis/zacks/062113/sgentakeda-report-data-adcetris-analyst-blog-tkpyy-sgen-biib-jazz.aspx?partner=rss_headlines
http://www.investopedia.com/stock-analysis/zacks/062113/sgentakeda-report-data-adcetris-analyst-blog-tkpyy-sgen-biib-jazz.aspx?partner=rss_headlines
No comments:
Post a Comment